

Amendment to the Appeal Brief:

Please replace Section V. Summary of Claimed Subject Matter of the Appeal Brief Filed July 31, 2006 with the following Section V. Summary of Claimed subject Matter:

**V. SUMMARY OF CLAIMED SUBJECT MATTER**

The instant Application includes four independent claims, claims 25, 55, 85, and 91.

**Claim 25**

Claim 25 recites a method in a computer system for processing hereditary data related to the use of clinical agents by a person (Specification page 2, paragraph 13 of U.S. Patent Application Publication No. 2002/0187483). The method comprises receiving a genetic test result value for the person (Specification page 6, paragraph 55; FIG. 6) and querying a computerized table listing polymorphism values and atypical clinical events associated with the polymorphism values (Specification page 6, paragraph 55; FIG. 6). It is determined if the genetic test result value is a polymorphism value associated with an atypical clinical event (Specification page 6, paragraphs 55 and 56; FIG. 6), and if so, a list of risk-associated agent is accessed and an interpretation of the genetic test result value and the list of risk-associated agents are output (Specification page 6, paragraphs 56 and 58; FIG. 6).

**Claim 55**

Claim 55 recites a computer system for processing hereditary data related to the use of clinical agents by a person (Specification page 2, paragraph 13). The system comprises a receiving component that receives a genetic test result value for the person (Specification page 3, paragraph 26, FIG. 1 and page 6, paragraph 55, FIG. 6) and a querying component for querying a computerized table listing polymorphism values and atypical clinical events associated with the polymorphism values (Specification page 3, paragraph 26, FIG. 1 and page 6, paragraph 55; FIG. 6). The system further comprises a first determining component that determines if the genetic

test result value is a polymorphism value associated with an atypical clinical event (Specification page 3, paragraph 26, FIG. 1 and page 6, paragraph 55; FIG. 6), an accessing component that accesses a list of risk-associated agents if the determining component determines that a genetic test result value is a polymorphism value associated with an atypical event (Specification page 3, paragraph 26, FIG. 1 and page 6, paragraph 56; FIG. 6), and an outputting component that outputs an interpretation of the genetic test result value and the list of risk-associated agents (Specification page 3, paragraph 26, FIG. 1 and page 6, paragraphs 56 and 58; FIG. 6).

#### **Claim 85**

Claim 85 recites a computer-readable medium containing instructions for processing hereditary data related to the use of clinical agents by a person (Specification page 3, paragraphs 26 and 27). The instructions comprise receiving a genetic test result value for the person (Specification page 6, paragraph 55; FIG. 6) and querying a computerized table listing polymorphism values and atypical clinical events associated with the polymorphism values (Specification page 6, paragraph 55; FIG. 6). The instructions further comprise determining if the genetic test result value is a polymorphism value associated with an atypical clinical event (Specification page 6, paragraphs 55 and 56; FIG. 6), and if so, accessing a list of risk-associated agents and outputting an interpretation of the genetic test result value and the list of risk-associated agents (Specification page 6, paragraphs 56 and 58; FIG. 6).

#### **Claim 91**

Claim 91 recites a method in a computer system for processing hereditary data related to the use of clinical agents by a person (Specification page 2, paragraph 13). The method comprises receiving a genetic test result value for the person (Specification page 6, paragraph 55; FIG. 6) and querying a computerized table listing polymorphism values and

atypical clinical events associated with the polymorphism values (Specification page 6, paragraph 55; FIG. 6). The method further comprises determining if the genetic test result value is a polymorphism value associated with an atypical clinical event (Specification page 6, paragraphs 55 and 56; FIG. 6), and if so, accessing a list of risk-associated agents (Specification page 6, paragraph 56; FIG. 6). An interpretation of the genetic test result value and the list of risk-associated agents are output (Specification page 6, paragraphs 56 and 58; FIG. 6) and it is determined if the person has been exposed to an agent on the list of risk-associated agents (Specification page 6, paragraph 58; FIG. 6).